CUBICIN RF 500 MG
DAPTOMYCIN : 500 MG · DIN 02465493 · CUBIST PHARMACEUTICALS LLC
Health Canada status: MARKETED
What is CUBICIN RF?
CUBICIN RF 500 MG contains DAPTOMYCIN : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02465493, held by CUBIST PHARMACEUTICALS LLC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 17-Jan-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CUBICIN RF used for?
CUBICIN® / CUBICIN® RF (daptomycin for injection) is indicated for complicated skin and skin structure infections (cSSSI) and Staphylococcus aureus bloodstream infections (bacteremia), including right-sided Staphylococcus aureus infective endocarditis (native valve), in adults and pediatric patients (1-17 years of age).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02465493 |
|---|---|
| Brand name | CUBICIN RF |
| Generic / active ingredient | DAPTOMYCIN : 500 MG |
| Manufacturer | CUBIST PHARMACEUTICALS LLC |
| Strength | 500 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01XX09 DAPTOMYCIN |
| AHFS class | 08:12.28.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Jan-2018 |
| Original market date | 2018-01-17 00:00:00 |
How is it stored and handled?
null
How is it supplied?
10 mL vial, 500 mg/vial
Is DAPTOMYCIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01XX09 DAPTOMYCIN. 3 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DAPTOMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02490838 |
| DAPTOMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02490463 |
| CUBICIN | 500 MG | POWDER FOR SOLUTION | CUBIST PHARMACEUTICALS LLC | DORMANT | DIN 02299909 |
| DAPTOMYCIN FOR INJECTION | 350 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02460009 |
| DAPTOMYCIN FOR INJECTION | 350 MG | POWDER FOR SOLUTION | DR REDDY'S LABORATORIES LTD | CANCELLED PRE MARKET | DIN 02526743 |
| DAPTOMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | ACCORD HEALTHCARE INC | CANCELLED POST MARKET | DIN 02494590 |
| DAPTOMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02460017 |
| DAPTOMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | CANCELLED PRE MARKET | DIN 02462117 |
| DAPTOMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | CANCELLED PRE MARKET | DIN 02511738 |
| DAPTOMYCIN FOR INJECTION RF | 500 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | CANCELLED PRE MARKET | DIN 02518856 |
Who else supplies DAPTOMYCIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DAPTOMYCIN appears in 47 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.